Monod Bio licenses AI-designed protein technologies to SignalChem Biotech for custom discovery assays
- Posted on August 27, 2026
- By Google News
- 0 Views
- 1 min read
In brief
Generating AI summary…
Monod Bio licenses AI-designed protein technologies to SignalChem Biotech for custom discovery assays
Monod Bio, a Seattle-based AI-enabled protein design company, and SignalChem Biotech Inc., a wholly-owned subsidiary of Sino Biological, Inc., today announced a non-exclusive licensing agreement covering Monod Bio’s proprietary LuxSit de novo luciferase technology and NovoBodies.